Submitted by Anonymous (not verified) on 20 October 2023 - 13:05
Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 51, Status: Authorised
Source: